Reduction of increased intraocular pressure in patients with open-angle glaucoma and increased intraocular pressure. Reduction of increased intraocular pressure in children with increased intraocular pressure and pediatric glaucoma.
active substance: latanoprost;
1 ml of solution contains latanoprost 0.05 mg;
excipients: sodium hydrogen phosphate, dodecahydrate; sodium dihydrogen phosphate, dihydrate; sodium chloride; benzalkonium chloride; purified water.
Latasopt Dosage form
Eye drops, solution.
Basic physical and chemical properties: colorless transparent solution.
Latasopt Pharmacotherapeutic group
Antiglaucoma drugs and miotics. Prostaglandin analogues. Code ATX S01E E01.
The active substance in latanoprost, a prostaglandin F2a analogue, is a selective agonist of the prostanoid FP receptor, which reduces intraocular pressure (IOP) by increasing the outflow of aqueous humor. The decrease in IOP in humans begins approximately 3-4 hours after the use of latanoprost, and the maximum effect is observed after 8-12 hours. The antihypertensive effect lasts for at least 24 hours.
Baseline studies have shown that latanoprost is effective as monotherapy. In addition, clinical studies of the combined use of latanoprost have been shown to show that it is also effective in combination with beta-blockers (timolol). Short-term (1 or 2 weeks) studies have shown that latanoprost is additive when used in combination with adrenergic agonists (dipivalyl epinephrine), oral carbonic anhydrase inhibitors (acetazolamide) and at least partially addicolistase.
Reduction of increased intraocular pressure in adult patients (including elderly patients) with open-angle glaucoma and increased intraocular pressure.
Reduction of high intraocular pressure in pediatric patients with high intraocular pressure and pediatric glaucoma.
Hypersensitivity to the active substance and / or to any of the other ingredients.
Interaction with other medicinal products and other forms of interaction
There are no comprehensive data on the interaction of latanoprost with other drugs.
A paradoxical increase in IOP has been reported after concomitant use of two prostaglandin analogues in the eyes. Therefore, it is not recommended to use two or more prostaglandins, prostaglandin analogues or their derivatives at the same time.
Method of application and dosage
The drug is intended for topical use.
Adults (including the elderly)
The recommended dose is 1 drop in the affected eye 1 time per day. The optimal effect is achieved when using the drug in the evening.
The drug should not be used more than once a day, as it is shown that more frequent use reduces the effectiveness of reducing intraocular pressure.